In:
Clinical Nuclear Medicine, Ovid Technologies (Wolters Kluwer Health), Vol. 45, No. 12 ( 2020-12), p. e512-e513
Abstract:
A 37-year-old man, treated case of left temporal glioblastoma presented with headache, seizures, and progressive right-sided weakness with MRI evidence of recurrence. Exploratory 68 Ga-PSMA PET/CT demonstrated PSMA expression in the recurrent lesion; it was decided to treat this patient with 177 Lu-PSMA-617. After 3 cycles of 177 Lu-PSMA-617, 68 Ga-PSMA PET/CT showed significant reduction in PSMA uptake and regression in size of lesion on MRI with improvement in patient’s symptoms and performance status. 177 Lu-/ 68 Ga-PSMA theranostics has potential in patients with recurrent glioblastoma multiforme when other therapeutic options are not feasible.
Type of Medium:
Online Resource
ISSN:
1536-0229
,
0363-9762
DOI:
10.1097/RLU.0000000000003142
Language:
English
Publisher:
Ovid Technologies (Wolters Kluwer Health)
Publication Date:
2020
detail.hit.zdb_id:
2045053-9
